Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | UMPS | P11172 | 3/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.37 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.37 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212359 | 0.85 | P2RY2 (0.48) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL12143145 | 0.84 | P2RY2 (0.48) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL13423823 | 0.84 | P2RY2 (0.48) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL3218046 | 0.84 | P2RY2 (0.48) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL12144308 | 0.84 | P2RY2 (0.48) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL15196243 | 0.84 | P2RY2 (0.48) | P2RY2LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL3218852 | 0.83 | P2RY2 (0.45) | P2RY2UMPSP2RY6P2RY4P2RY14 | |
| SCHEMBL3221041 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13423829 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL13455784 | 0.83 | SLC28A1 (0.54) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | P2RY2 1891/4885LMNA 2265/4885THRB 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.